Zenas BioPharma, Inc.

NasdaqGS:ZBIO Stock Report

Market Cap: US$1.2b

Zenas BioPharma Dividends and Buybacks

Dividend criteria checks 0/6

Zenas BioPharma does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-27.0%

Buyback Yield

Total Shareholder Yield-27.0%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Apr 30

Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026

Summary Zenas BioPharma, Inc. maintains a Strong Buy rating, driven by obexelimab's positive phase 3 results in IgG4-RD and regulatory filings planned for 2026. ZBIO is advancing obexelimab into the large SLE market, with phase 2 SunStone topline and biomarker data expected in Q4 2026. Pipeline expansion includes ZB014, a half-life extended anti-CD19/FcγRIIb mAb aiming for once-monthly dosing, and CNS-penetrant BTK inhibitor orelabrutinib in phase 3 for MS. ZBIO's cash runway extends into Q2 2027, with potential for further extension into Q4 2027 upon obexelimab approval. Read the full article on Seeking Alpha
Analysis Article • Dec 24

Analysts' Revenue Estimates For Zenas BioPharma, Inc. (NASDAQ:ZBIO) Are Surging Higher

Zenas BioPharma, Inc. ( NASDAQ:ZBIO ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Jul 11

Here's Why We're Watching Zenas BioPharma's (NASDAQ:ZBIO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 13

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Oct 22

Zenas Bio: Recent IPO With Late-Stage Candidate

Summary Zenas BioPharma, Inc.'s obexelimab targets CD19 and FcγRIIb to modulate B-cells, aiming to treat multiple autoimmune diseases with fewer side effects. Phase 2 data for obexelimab in IgG4-RD showed strong clinical improvement and a high complete remission rate, with manageable adverse events. Zenas has a solid financial position post-IPO, with recent funding and a collaboration with Bristol-Myers Squibb, ensuring a decent cash runway. Despite the promising late-stage asset, I remain cautious due to the uncertainties surrounding recent IPOs and limited financial data. Read the full article on Seeking Alpha

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ZBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZBIO's dividend payments have been increasing.

Dividend Yield vs Market

Zenas BioPharma Dividend Yield vs Market
How does ZBIO dividend yield compare to the market?
SegmentDividend Yield
Company (ZBIO)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.5%
Analyst forecast (ZBIO) (up to 3 years)0%

Notable Dividend: Unable to evaluate ZBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ZBIO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ZBIO has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/16 21:40
End of Day Share Price 2026/06/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zenas BioPharma, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yigal NochomovitzCitigroup Inc
Cory KasimovEvercore ISI
Yatin SunejaGuggenheim Securities, LLC